Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an announcement.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for May 28, 2025, which will be held both physically and virtually. The meeting will address key resolutions including the approval of the 2024 annual report, financial statements, and remuneration plans for directors and supervisors. Additionally, a special resolution will be considered regarding the repurchase of H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. operates within the pharmaceutical industry, focusing on the development of innovative drugs and biotechnological solutions. The company is known for its work in the bio-medicine sector, particularly in Beijing’s Daxing Bio-Medicine Industry Park.
YTD Price Performance: 34.12%
Average Trading Volume: 186,043
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.54B
For an in-depth examination of 2315 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue